• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1375603-36-3 (VT-464 (racemate))

1

Identification

VT-464 (racemate) VT-464 (racemate)
Name VT-464 (racemate)
Formula C18H17F4N3O3
MW 399.34
CAS No. 1375603-36-3
EINECS
Smiles FC(F)OC1=C(OC(F)F)C=C(C=CC(C(C2=CNN=N2)(C(C)C)O)=C3)C3=C1
Synonyms VT464 racemate;VT 464 racemate; 1-(6,7-bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol
InChI InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)
2

Introduction

VT-464 racemate is the racemate form of VT-464, which is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM)inhibition. IC50 value: 69 nM(VT-464, h-CYP17 Lyase) [1] Target: CYP17 Lyase inhibitor in vitro: VT-464, a non-steroidal small molecule inhibits androgen production without mineralocorticoid excess or cortisol depletion by selective inhibition of CYP17 17,20-lyase.

Background Information

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50: 69 nM. ......by BOC Sciences
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000010692

Storage condition

Solubility

DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways Metabolic Enzyme/Protease
Target Cytochrome P450
Research Area Cancer
Indications Castration-resistant Prostate Cancer
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
VT-464 (racemate) Viamet Pharmaceuticals, Inc. Castration-resistant Prostate Cancer 2013/12/6 Phase 2 Clinical
VT-464 (racemate) - No Development Reported
7

Safety Data of VT-464 (racemate)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Apexbio Technology LLC 5mg/USD332();10mg/USD475();50mg/USD1425();100mg/USD1995() USA
BOC Sciences
CHEMSCENE, LLC 5mg/USD420();10mg/USD600() USA
MedChemexpress Co., Ltd. 5mg/USD420();10mg/USD600() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD420();10mg/USD600() China
10

Related Products

Other Forms of 1375603-36-3

Name CAS No Formula MW
VT-464 1610537-15-9 C18H17F4N3O3 399.34
VT-464 (R enantiomer) 1375603-38-5 C18H17F4N3O3 399.34

Recommended Compounds in Cytochrome P450

Name CAS No Formula MW
Dafadine-A 1065506-69-5 C23H25N3O3 391.46
VT-464 1610537-15-9 C18H17F4N3O3 399.34
Isosilybin 72581-71-6 C25H22O10 482.44
Memantine (hydrochloride) 41100-52-1 C12H22ClN 215.76
Clarithromycin 81103-11-9 C38H69NO13 747.95
(+)-Ketoconazole 142128-59-4 C26H28Cl2N4O4 531.43
(+)-Ketoconazole 142128-59-4 C26H28Cl2N4O4 531.4309
Galangin 548-83-4
Bergapten 484-20-8 C12H8O4 216.19
Naringin 10236-47-2 C27H32O14 580.53
Diosmetin 520-34-3 C16H12O6 300.26
Fenofibrate 49562-28-9 C20H21ClO4 360.83
Bergaptol 486-60-2 C11H6O4 202.1629
Talarozole (R enantiomer) 870093-23-5 C21H23N5S 377.5058
Choline Fenofibrate 856676-23-8 C22H28ClNO5 421.91
Talarozole 201410-53-9 C21H23N5S 377.51
Isavuconazole 241479-67-4 C22H17F2N5OS 437.4650864
Cobicistat 1004316-88-4 C40H53N7O5S2 776.02
Methoxsalen 298-81-7 C12H8O4 216.19
TAK-700 (R-form) 752243-39-3 C18H17N3O2 307.35

Recommended Compounds in Same Indication

Name CAS No Formula MW
VT-464 1610537-15-9 C18H17F4N3O3 399.34
11

Route of Synthesis

12

References

13

More Information

VT-464 (racemate)

Tags: buy 1375603-36-3 IC50 | 1375603-36-3 price | 1375603-36-3 cost | 1375603-36-3 solubility | 1375603-36-3 purchase | 1375603-36-3 manufacturer | 1375603-36-3 research buy | 1375603-36-3 order | 1375603-36-3 MSDS | 1375603-36-3 chemical structure | 1375603-36-3 Storage condition | 1375603-36-3 molecular weight | 1375603-36-3 mw | 1375603-36-3 datasheet | 1375603-36-3 supplier | 1375603-36-3 cell line | 1375603-36-3 NMR | 1375603-36-3 MS | 1375603-36-3 IR | 1375603-36-3 solubility | 1375603-36-3 Safe information | 1375603-36-3 Qc and Spectral Information | 1375603-36-3 Clinical Information | 1375603-36-3 Clinical Trial | 1375603-36-3 Route of Synthesis | 1375603-36-3 storage condition | 1375603-36-3 diseases and conditions | 1375603-36-3 flash point | 1375603-36-3 boiling point | 1375603-36-3 melting point | 1375603-36-3 storage condition | 1375603-36-3 brand